Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine versus conventional care regimens within a phase 3...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Mol Sci
Autori principali: Pleyer, Lisa, Döhner, Hartmut, Dombret, Hervé, Seymour, John F., Schuh, Andre C., Beach, CL, Swern, Arlene S., Burgstaller, Sonja, Stauder, Reinhard, Girschikofsky, Michael, Sill, Heinz, Schlick, Konstantin, Thaler, Josef, Halter, Britta, Machherndl Spandl, Sigrid, Zebisch, Armin, Pichler, Angelika, Pfeilstöcker, Michael, Autzinger, Eva M., Lang, Alois, Geissler, Klaus, Voskova, Daniela, Sperr, Wolfgang R., Hojas, Sabine, Rogulj, Inga M., Andel, Johannes, Greil, Richard
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5343949/
https://ncbi.nlm.nih.gov/pubmed/28212292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18020415
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi